Adalimumab in Rheumatoid Arthritis. An Investigation of Changes in Disease Activity and Course of Joint Destruction by Use of 3 Tesla Whole-Body MRI, Dedicated 3 Tesla MRI and CT of the Hand, and Soluble Biomarkers.

Trial Profile

Adalimumab in Rheumatoid Arthritis. An Investigation of Changes in Disease Activity and Course of Joint Destruction by Use of 3 Tesla Whole-Body MRI, Dedicated 3 Tesla MRI and CT of the Hand, and Soluble Biomarkers.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Acronyms WRAP
  • Most Recent Events

    • 18 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Planned End Date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 15 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top